The Brugada syndrome - An update

Internal Medicine

Volumn 44, Issue 12, 2006, Pages 1224-1231

  Shimizu, Wataru ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Brugada syndrome; Diagnosis; Prognosis; Risk stratification; ST segment; Therapy; Ventricular fibrillation

Indexed keywords

AJMALINE; ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIBENZOLINE; CILOSTAZOL; DENOPAMINE; DISOPYRAMIDE; FLECAINIDE; ISOPRENALINE; LIDOCAINE; MEXILETINE; PHOSPHODIESTERASE III INHIBITOR; PILSICAINIDE; PROCAINAMIDE; QUINIDINE; SODIUM CHANNEL BLOCKING AGENT;

BRUGADA SYNDROME; CLINICAL FEATURE; CONSENSUS; DEFIBRILLATOR; ELECTROPHYSIOLOGY; GENETIC LINKAGE; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; HUMAN GENOME; PHENOTYPE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCN5A GENE; ST SEGMENT ELEVATION; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; BUNDLE-BRANCH BLOCK; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; HUMANS; PROGNOSIS; SYNDROME; VENTRICULAR FIBRILLATION;

EID: 31444441326     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.1224     Document Type: Review

References (58)

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 20: 1391-1396, 1992.
2. 3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 97: 457-460, 1998.
3. Alings M, Wilde A. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 99: 666-673, 1999.
4. Antzelevitch C, Brugada P, Brugada J, et al. Brugada syndrome. A decade of progress. Circ Res 91: 1114-1118, 2002.
5. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105: 1342-1347, 2002.
6. Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 106: 2514-2519, 2002.
7. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 105: 73-78, 2002.
8. Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada Syndrome. Report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111: 659-670, 2005.
9. Atarashi H, Ogawa S, Harumi K, et al. Idiopathic Ventricular Fibrillation Investigators: Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome. Idiopathic Ventricular Fibrillation Investigators. J Am Coll Cardiol 37: 1916-1920, 2001.
10. Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 95: 2277-2285, 1997.
11. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 9: 508-512, 1998.
12. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 27: 1061-1070, 1996.
13. Nademanee & Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96: 2595-2600, 1997.
14. Vatta M, Dumaine R, Varghese G, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 11: 337-345, 2002.
15. Kanda M, Shimizu W, Matsuo K, et al. Electrophysiologic characteristics and implication of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol 39: 1799-1805, 2002.
16. Eckardt L, Probst V, Smits JP, et al. Long-term rognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 111: 257-263, 2005.
17. Shimizu W. Editorial comment, Gender difference and drug challenge in Brugada syndrome. J Cardiovasc Electrophysiol 15: 70-71, 2004.
18. Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 106: 2004-2011, 2002.
19. Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the Brugada-type electrocardiogram after surgical castration: a role for testosterone and an explanation for the male preponderance. PACE 26: 1551-1553, 2003.
20. Shimizu W, Matsuo & Satomi K, et al. Role of testosterone on male predominance in Brugada syndrome. Circulation 110: III-500, 2004.
21. Matsuo K, Kurita T, Inagaki M, et al. The circadian pattern of the development of ventricular fibrillation in patients with Brugada syndrome. Eur Heart J 20: 465-470, 1999.
22. Mizumaki K, Fujiki A, Tsuneda T, et al. Vagal activity modulates spontaneous augmentation of ST elevation in the daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 15: 667-673, 2004.
23. Morita H, Kusano-Fukushima K, Nagase S, et al. Atrial fibrillation and atrial vulnerability in patients with Brugada syndrome. J Am Coll Cardiol 40: 1437-1444, 2002.
24. Eckardt L, Kirchhof P, Johna R, et al. Wolff-Parkinson-White syndrome associated with Brugada syndrome. PACE 24: 1423-1424, 2001.
25. Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and response to drugs of ST segment elevation in the Brugada syndrome: Clinical implication of 87-leads body surface potential mapping and its application to 12-leads electrocardiograms. J Cardiovase Electrophysiol 11: 396-404, 2000.
26. Smits JP, Eckardt L, Probst V, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 40: 350-356, 2002.
27. Pitzalis MV, Anaclerio M, Iacoviello M, et al. QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 42: 1632-1637, 2003.
28. Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 37: 1628-1634, 2001.
29. Brugada R, Brugada. J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101: 510-515, 2000.
30. Shimizu W, Antzelevitch C, Suyama K, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 11: 1320-1329, 2000.
31. Shimizu W, Aiba T, Kurita T, Kamakura S. Paradoxical abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J Cardiovasc Electrophysiol 12: 1418-1421, 2001.
32. Morita H, Morita ST, Nagase S, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 42: 1624-1631, 2003.
33. Wolpert C, Echternach C, Veltmann C, et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2: 254-260, 2005.
34. Shimizu W. Acquired Forms of Brugada Syndrome (Antzelevitch C review) in: The Brugada Syndrome: From Bench to Bedside, Chapter 14, Blackwell Futura, UK, 2004: 166-177.
35. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 346: 1591-1592, 2002.
36. Antzelevitch C, Brugada R. Fever and Brugada syndrome. PACE 25: 1537-1539, 2002.
37. Myers GB. Other QRS-T patterns that may be mistaken for myocardial infarction. IV. Alterations in blood potassium; myocardial ischemia; subepicardial myocarditis; distortion associated with arrhythmias. Circulation 2: 75-93, 1950.
38. Kataoka H. Electrocardiographic patterns of the Brugada syndrome in right ventricular infarction/ischemia. Am J Cardiol 86: 1056, 2000.
39. Noda T, Shimizu W, Taguchi A, et al. ST segment elevation and ventricular fibrillation without coronary spasm by intra coronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 40: 1841-1847, 2002.
40. Morita H, Fukushima-Kusano K, Nagase S, et al. Sinus node function in patients with Brugada-type ECG. Circ J 68: 473-476, 2004.
41. Kamakura S. Clinical profiles and prognosis of patients with Brugada syndrome. - A multi-center study for risk stratification and management in Japan -. Circ J 69: 289 (Suppl I), 2005.
42. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 392: 293-296, 1998.
43. Weiss R, Barmada MM, Nguyen T, et al. Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3. Circulation 105: 707-713, 2002.
44. Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: Current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med 2: 408-414, 2005.
45. + channel mutation causing both long-QT and Brugada syndromes. Circ Res 85: 1206-1213, 1999.
46. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 104: 3081-3086, 2001.
47. Viswanathan PC, Bezzina CR, George AL Jr, Roden DM, Wilde AA, Balser JR. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 104: 1200-1205, 2001.
48. Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intra-cellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. Circ Res 90: E11-E16, 2002.
49. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Cire Res 62: 116-126, 1988.
50. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 Reentry? Circulation 87: 562-572, 1993.
51. Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 93: 372-379, 1996.
52. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 100: 1660-1666, 1999.
53. Aiba T, Shimizu W, Hidaka I, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: High resolution optical mapping study. J Am Coll Cardiol 2006 (in press).
54. Hermida JS, Denjoy I, Clerc J, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 43: 1853-1860, 2004.
55. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110: 1731-1737, 2004.
56. Shimizu W, Kamakura S. Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol 34: 173-175, 2001.
57. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 13: 698-701, 2002.
58. Suzuki H, Torigoe K, Numata O, Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 11: 1277-1280, 2000.